Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7400751 | 0.75 | SCN9A (0.43) | OPRM1OPRL1GRM2GRM5HTR1A | |
| SCHEMBL8380654 | 0.74 | SRD5A1 (0.38) | OPRM1OPRL1GRM5 | |
| SCHEMBL2530710 | 0.74 | RXFP1 (0.43) | OPRM1OPRL1GRM2RXFP1GRM5 | |
| SCHEMBL9053676 | 0.73 | OPRM1 (0.41) | OPRM1OPRL1GRM2GRM5HTR1A | |
| SCHEMBL8631856 | 0.73 | KMT2A (0.66) | OPRM1OPRL1DDB1CRBNEPHX2 | |
| SCHEMBL7555132 | 0.73 | DDB1 (0.45) | DDB1CRBNKDM4EEPHX2 | |
| SCHEMBL2536247 | 0.73 | DDB1 (0.72) | OPRM1OPRL1DDB1CRBNKDM4E | |
| SCHEMBL11097554 | 0.73 | MGLL (0.46) | DDB1CRBNKDM4EEPHX2 | |
| SCHEMBL8632730 | 0.73 | ALOX5 (0.50) | DDB1CRBNKDM4EEPHX2 | |
| SCHEMBL20139976 | 0.72 | JAK2 (0.42) | GRM5HTR1AADRA1AADRA1BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838439-B2 | Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-04 | — | — | US | disclosed |
| CN-1129603-C | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 2003-12-03 | — | — | CN | disclosed |
| US-20020065391-A1 | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| CN-1182746-A | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 1998-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065391-A1 | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, ICAM1, ITGB4 | OPRM1 1193/4885OPRL1 640/4885DDB1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.